Pharmacokinetic herb-drug interactions (Part 2): Drug interactions involving popular botanical dietary supplements and their clinical relevance

Planta Medica

Volumn 78, Issue 13, 2012, Pages 1490-1514

  Gurley, Bill J ^a   Fifer, Espero Kim ^b   Gardner, Zoë ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

ATP binding cassette transporters; black cohosh; black pepper; botanical dietary supplements; cytochrome P450 enzymes; Echinacea; garlic; Ginkgo biloba; ginseng; goldenseal; herb drug interaction; kava; methylenedioxyphenyl containing compounds; milk thistle; piperine; plant secondary metabolites; Schisandra; solute carrier membrane transport proteins; St.John's wort; transferases

Indexed keywords

ALLICIN; AMITRIPTYLINE; BERBERINE; BLACK PEPPER EXTRACT; CIMICIFUGA RACEMOSA EXTRACT; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; ECHINACEA PURPUREA EXTRACT; FEXOFENADINE; GARLIC EXTRACT; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCOSIDE; HYDRASTINE; HYDRASTIS CANADENSIS EXTRACT; HYPERICUM PERFORATUM EXTRACT; ISORHAMNETIN; KAEMPFEROL; KAVA; PLANT EXTRACT; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SCHISANDRA CHINENSIS EXTRACT; SILYBUM MARIANUM EXTRACT; SIMVASTATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE; WARFARIN;

ANXIETY; ARTICLE; BLACK PEPPER; CELL STRAIN HEPG2; CIMICIFUGA RACEMOSA; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; ECHINACEA ANGUSTIFOLIA; ECHINACEA PURPUREA; ENZYME ACTIVITY; GARLIC; GINKGO BILOBA; GINSENG; HEPATITIS; HERB DRUG INTERACTION; HOT FLUSH; HUMAN; HYDRASTIS; HYPERICUM PERFORATUM; IN VITRO STUDY; INSOMNIA; LIVER CIRRHOSIS; LIVER TOXICITY; MEDICINAL PLANT; MENOPAUSAL SYNDROME; NONHUMAN; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PREMENSTRUAL SYNDROME; PROTEIN EXPRESSION; SCHISANDRA; SCHISANDRA CHINENSIS; SCIENTIFIC LITERATURE; SIDE EFFECT; SILYBUM MARIANUM; SINGLE DRUG DOSE; STRESS;

ALLIUM SATIVUM; CIMICIFUGA DAHURICA; GINKGO BILOBA; HYDRASTIS CANADENSIS; HYPERICUM PERFORATUM; PANAX GINSENG; PIPER METHYSTICUM; PIPER NIGRUM; SCHISANDRA; SCHISANDRA CHINENSIS; SILYBUM MARIANUM;

EID: 85027924798     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0031-1298331     Document Type: Article

References (422)

1. Borrelli F, Izzo A A., Ernst E. Pharmacological effects of Cimicifuga racemosa. Life Sci 2003 73 1215-1229
2. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause 2003 10 58-64
3. Shams T, Setia M S., Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta analysis. Altern Health Med 2010 16 36-44
4. Viereck V, Emons G, Wuttke W. Black cohosh: just another phytoestrogen? Trend Endocrinol Metab 2005 16 214-221
5. Li J X., Yu Z Y. Cimicifugae rhizoma: from origins, bioactive constituents to clinical outcomes. Curr Med Chem 2006 13 2927-2951
6. van Breeman R B., Liang W, Banuvar S, Shulman L P., Pang Y, Tao Y, Nikolic D, Krock K M., Fabricant D S., Chen S-N, Hedayat S, Bolton J L., Pauli G F., Piersen C E., Krause E C., Geller S E., Farnsworth N R. Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh. Clin Pharmacol Ther 2010 87 219-225
7. Tsukamoto S, Aburatani M, Ohta T. Isolation of CYP3A4 inhibitors from the black cohosh (Cimicifuga racemosa). eCAM 2005 2 223-226
8. Huang Y, Jiang B, Nuntanakorn P, Kennelly E J., Shord S, Lawal T O., Soni K K., Mahady G B. Fukinolic acid derivatives and triterpene glycosides from black cohosh inhibit CYP isozymes, but are not cytotoxic to Hep-G2 cells in vitro. Curr Drug Saf 2010 5 118-124
9. Jiang B, Kronenberg F, Nuntanakorn P, Qiu M-H, Kennelly E J. Evaluation of the botanical authenticity and phytochemical profile of black cohosh products by high-performance liquid chromatography with selected ion monitoring liquid chromatography-mass spectrometry. J Agric Food Chem 2006 54 3242-3253
10. Sevior D K., Hokkanen J, Tolonen A, Abass K, Tursas L, Pelkonen O, Ahokas J T. Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail. Xenobiotica 2010 40 245-254
11. Gurley B J., Barone G W., Williams D K., Carrier J, Breen P, Yates C R., Song P, Hubbard M A., Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2006 34 69-74
12. Gurley B, Hubbard M A., Williams D K., Thaden J, Tong Y, Gentry W B., Breen P, Carrier D J., Cheboyina S. Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin. J Clin Pharmacol 2006 46 201-213
13. Gurley B J., Gardner S F., Hubbard M A., Williams D K., Gentry W B., Khan I A., Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 2005 77 415-426
14. Fuchikami H, Satoh H, Tsujimoto M, Ohdo S, Ohtani H, Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab Dispos 2006 34 577-582
15. Basch E, Ulbricht C, Basch S, Dalton S, Ernst E, Foppa I, Szapary P, Tiffany N, Orlando C W., Vora M. An evidence-based systematic review of Echinacea (E. angustifolia DC, E. pallida, E. purpurea) by the Natural Standard Research Collaboration. J Herb Pharmacother 2005 5 57-88
16. Barnes J, Anderson L A., Gibbons S, Phillipson J D. Echinacea species (Echinacea angustifolia (DC.) Hell., Echinacea pallida (Nutt.) Nutt., Echinacea purpurea (L.) Moench): a review of their chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2005 57 929-954
17. Schoop R, Klein P, Suter A, Johnston S L. Echinacea in the prevention of induced rhinovirus colds: a meta analysis. Clin Ther 2006 28 174-183
18. Shah S A., Sander S, White C M., Rinaldi M, Coleman C I. Evaluation of Echinacea for the prevention and treatment of the common cold: a meta analysis. Lancet Infect Dis 2007 7 473-480
19. Linde K, Barrett B, Bauer R, Melchart D, Woelkart K. Echinacea for preventing and treating the common cold. Cochrane Database Syst Rev 2006 1 CD000530
20. Christensen L P., Brandt K. Acetylenes and psoralens. In: Crozier A Clifford M N. Ashihara H editors Plant secondary metabolites: occurrence, structure and role in the human diet. Oxford Blackwell 2006 137-173
21. Gilroy C M., Steiner J F., Byers T, Shapiro H, Georgian W. Echinacea and truth in labeling. Arch Intern Med 2003 163 699-704
22. Jager H, Meinel L, Dietz B, Lapke C, Bauer R, Merkle H P., Heilmann J. Transport of alkamides from Echinacea species through Caco-2 monolayers. Planta Med 2002 68 469-471
23. Matthias A, Blanchfield JT, Penman KG, Toth I, Lang C-S, De Voss JJ, Lehmann RP. Permeability studies of alkylamides and caffeic acid conjugates from Echinacea using a Caco-2 cell monolayer model. J Clin Pharm Ther 2004 29 7-13
24. Dietz B, Heilmann J, Bauer R. Absorption of dodeca-2E,4E,8Z,10E/Z- tetraenoic acid isobutylamides after oral application of Echinacea purpurea tincture. Planta Med 2001 67 863-864
25. Woelkart K, Koidl C, Grisold A, Gangemi JD, Turner RB, Marth E, Bauer R. Bioavailability and pharmacokinetics of alkamides from the roots of Echinacea angustifolia in humans. J Clin Pharmacol 2005 45 683-689
26. Matthias A, Addison R S., Penman K G., Dickinson R G., Bone K M., Lehmann R P. Echinacea alkamide disposition and pharmacokinetics in humans after tablet ingestion. Life Sci 2005 77 2018-2029
27. Matthias A, Gillam E M. J., Penman K G., Matovic N J., Bone K M., De Voss J J., Lehmann R P. Cytochrome P450 enzyme-mediated degradation of Echinacea alkylamides in human liver microsomes. Chem Biol Interact 2005 155 62-70
28. Toselli F, Matthias A, Bone K M., Gillam E M. J., Lehmann R P. Metabolism of the major Echinacea alkylamide N -isobutyldodeca-2E,4E,8Z,10Z-tetraenamide by human recombinant cytochrome P450 enzymes and human liver microsomes. Phytother Res 2010 24 1195-1201
29. Toselli F, Matthias A, Gillam E M. J. Echinacea metabolism and drug interactions: the case for standardization of a complementary medicine. Life Sci 2009 85 97-106
30. Budzinski J W., Foster B C., Vandenhoek S, Arnason J T. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000 7 273-282
31. Foster B C., Vandenhoek S, Hana J, Krantis A, Akhtar M H., Bryan M, Budzinski J W., Ramputh A, Arnason J T. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine 2003 10 334-342
32. Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomedicine 2004 11 98-104
33. Yale S H., Glurich I. Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9. J Altern Complement Med 2005 11 433-439
34. Raner G M., Cornelious S, Moulick K, Wang Y, Mortensen A, Cech N B. Effects of herbal products and their constituents on human cytochrome P450(2E1) activity. Food Chem Toxicol 2007 45 2359-2365
35. Hellum B H., Nilsen O G. The in vitro inhibitory potential of trade herbal products on human CYP2D6-mediated metabolism and the influence of ethanol. Basic Clin Pharmacol Toxicol 2007 101 350-358
36. Budzinski J W., Trudeau V L., Drouin C E., Panahi M, Arnason J T., Foster B C. Modulation of human cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) in Caco-2 cell monolayers by selected commercial-source milk thistle and goldenseal products. Can J Physiol Pharmacol 2007 85 966-978
37. Budzinski J W., Foster B C., Trudeau V L., Drouin C E., Bafi-Yeboa N, Arnason J T. The interaction of selected phytochemicals, HIV drugs, and commercial-source herbal teas and capsules with human cytochrome P450 3A4 and P-glycoprotein. Pharm Biol 2008 46 53-65
38. Hellum B H., Nilsen O G. In vitro inhibition of CYP3A4 metabolism and P-glycoprotein-mediated transport by trade herbal products. Basic Clin Pharmacol Toxicol 2008 102 466-475
39. Modarai M, Gertsch J, Suter A, Heinrich M, Kortenkamp A. Cytochrome P450 inhibitory action of Echinacea preparations differs widely and co-varies with alkylamide content. J Pharm Pharmacol 2007 59 567-573
40. Hansen T S., Nilsen O G. In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin Pharmacol Toxicol 2008 103 445-449
41. Modarai M, Silva E, Suter A, Herinrich M, Kortenkamp A. Safety of herbal medicinal products: Echinacea and selected alkylamides do not induce CYP3A4 mRNA expression. Evid Based Complement Alternat Med 2011 Article ID 213021, 7 pages
42. Modarai M, Yang M, Suter A, Kortenkamp A, Heinrich M. Metabolomic profiling of liquid Echinacea medicinal products with in vitro inhibitory effects on cytochrome P450 3A4 (CYP3A4). Planta Med 2010 76 378-385
43. Romiti N, Pellati F, Nieri P, Benvenuti S, Adinolfi B, Chieli E. P-glycoprotein inhibitory activity of lipophilic constituents of Echinacea pallida roots in a human proximal cell line. Planta Med 2008 74 264-266
44. Hansen T S., Nilsen O G. Echinacea purpurea and P-glycoprotein drug transport in Caco-2 cells. Phytother Res 2009 23 86-91
45. Mrozikiewicz P M., Bogacz A, Karasiewicz M, Mikolajczak P L., Ozarowski M, Seremak-Mrozikiewicz A, Czerny B, Bobkiewicz-Kozlowska T, Grzeskowiak E. The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level. Phytomedicine 2010 17 830-833
46. Gorski J C., Huang S M., Mitchell A P., Hamman A, Hilligoss J K., Zaheer N A., Desai M, Miller M, Hall S D. The effect of echinacea (Echinacea purpurea) on cytochrome P450 activity in vivo. Clin Pharmacol Ther 2004 75 89-100
47. Gorski J C., Jones D R., Haehner-Daniels B D., Hamman M A., O'Mara E M., Hall S D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 1998 64 133-143
48. Gorski J C., Vannaprasaht S, Hamman M A., Ambrosius W T., Bruce M A., Haehner-Daniels B, Hall S D. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 2003 74 275-287
49. Gurley B J., Swain A, Hubbard M A., Williams D K., Barone G, Hartsfield F, Tong Y, Carrier D J., Cheboyina S, Battu S K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol Nutr Food Res 2008 52 755-763
50. Gurley B J., Gardner S F., Hubbard M A., Williams D K., Gentry W B., Carrier J, Khan I A., Edwards D J., Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004 76 428-440
51. Penzak S R., Robertson S M., Hunt J D., Chairez C, Malati C Y., Alfaro R M., Stevenson J M., Kovacs J A. Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects. Pharmacotherapy 2010 30 797-805
52. Gurley B J., Swain A, Williams D K., Barone G, Battu S K. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St John's wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res 2008 52 772-779
53. Freeman C, Spelman K. A critical evaluation of drug interactions with Echinacea spp. Mol Nutr Food Res 2008 52 789-798
54. Crozier A, Yokota T, Jaganath I B., Marks S C., Saltmarsh M, Clifford M N. Secondary metabolites in fruits, vegetables, beverages and other plant-based dietary components. In: Crozier A Clifford M N. Ashihara H editors Plant secondary metabolites: occurrence, structure and role in the human diet. Oxford Blackwell 2006 208-302
55. Stevinson C, Pittler M H., Ernst E. Garlic for treating hypercholesterolemia: a meta analysis of randomized clinical trials. Ann Intern Med 2000 133 420-429
56. Gardner C D., Lawson L D., Block E, Chatterjee L M., Kiazand A, Balise R R., Kraemer H C. Effect of raw garlic vs. commercial garlic supplements on plasma lipid concentrations in adults with moderate hypercholesterolemia. Arch Intern Med 2007 167 346-353
57. Pittler M H., Ernst E. Clinical effectiveness of garlic (Allium sativum). Mol Nutr Food Res 2007 51 1382-1385
58. Chen Z-Y, Jiao R, Ma K Y. Cholesterol-lowering nutraceuticals and functional foods. J Agric Food Chem 2008 56 8761-8773
59. Lawson L D., Wang Z J., Hughes B G. Identification and HPLC quantitation of the sulfides and dialk(en)yl thiosulfinates in commercial garlic products. Planta Med 1991 57 363-370
60. Lawson L D., Gardner C D. Composition, stability, and bioavailability of garlic products used in a clinical trial. J Agric Food Chem 2005 53 6254-6261
61. Amagase H. Clarifying the real bioactive constituents of garlic. J Nutr 2006 136 716S-725S
62. Matsuura H. Saponins in garlic as modifiers of the risk of cardiovascular disease. J Nutr 2001 131 1000S-1005S
63. Simons L A., Balasubramaniam S, von Konigsmark M, Parfitt A, Simons J, Peters W. On the effect of garlic oil on plasma lipids and lipoproteins in mild hypercholesterolaemia. Atherosclerosis 1995 113 219-225
64. Berthold H K., Sudhop T, von Bergman K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism: a randomized controlled trial. JAMA 1998 279 1900-1902
65. Smith T J., Yang C S. Effect of organosulfur compounds from garlic and cruciferous vegetables on drug metabolism enzymes. Drug Metabol Drug Interact 2000 17 23-49
66. Yang C S., Chhabra S K., Hong J-Y, Smith T J. Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic. J Nutr 2001 131 1041S-1045S
67. Morris C R., Chen S C., Zhou L, Schopfer L M., Ding X, Mirvish S S. Inhibition by allyl sulfides and phenethyl isothiocyanate of methyl-n-pentylnitrosamine depentylation by rat esophageal microsomes, human, and rat CYP2E1, and rat CYP2A3. Nutr Cancer 2004 48 54-63
68. Wargovich M J. Diallylsulfide and allylmethylsulfide are uniquely effective among organosulfur compounds in inhibiting CYP2E1 protein in animal models. J Nutr 2006 136 832S-834S
69. Black G P., Collins K S., Blacquiere D P., Forkert P-G. Formation of N-alkylprotoporphyrin IX from metabolism of diallyl sulfone in lung and liver. Drug Metab Dispos 2006 34 895-900
70. Haber D, Siess M H., Canivenc-Lavier M C., Le Bon A M., Suschetet M. Differential effects of dietary diallyl sulfide and diallyl disulfide on rat intestinal and hepatic drug-metabolizing enzymes. J Toxicol Environ Health 1995 44 423-434
71. Siess M, Le Bon A M., Canivenc-Lavier M C., Suschetet M. Modification of hepatic drug-metabolizing enzymes in rats treated with alkyl sulfides. Cancer Lett 1997 120 195-201
72. Wu C C., Sheen L Y., Chen H-W, Kuo W W., Tsai S J., Lii C-K. Differential effects of garlic oil and its three major organosulfur components on the hepatic detoxification system in rats. J Agric Food Chem 2002 50 378-383
73. Tsai C-W, Yang J-J, Chen H-W, Sheen L-Y, Lii C-K. Garlic organosulfur compounds upregulate the expression of the pi class of glutathione S-transferase in rat primary hepatocytes. J Nutr 2005 135 2560-2565
74. Zhang P, Noordine M-L, Cherbuy C, Vaugelade P, Pascussi J M., Due P-H, Thomas M. Different activation patterns of rat xenobiotic metabolism genes by two constituents of garlic. Carcinogenesis 2006 27 2090-2095
75. Krizkova J, Burdova K, Hudecek J, Stiborova M, Hodek P. Induction of cytochromes P450 in small intestine by chemopreventative compounds. Neuro Endocrinol Lett 2008 29 717-721
76. Lubet R A., Yao R, Grubbs C J., You M, Wang Y. Induced expression of drug metabolizing enzymes by preventive agents: role of the antioxidant response element. Chem Biol Interact 2009 182 22-28
77. Fisher C D., Augustine L M., Maher J M., Nelson D M., Slitt A L., Klaassen C D., Lehman-McKeeman L D., Cherrington N J. Induction of drug metabolizing enzymes by garlic and allyl sulfide compounds via activation of constitutive androstane receptor and nuclear factor E2-related factor 2. Drug Metab Dispos 2007 35 995-1000
78. Engdal S, Nilsen O G. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients. Phytother Res 2009 23 906-912
79. Zou L, Harkey M R., Henderson G L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002 71 1579-1589
80. Foster B C., Foster M S., Vandenhoek S, Krantis A, Budzinski J W., Arnason J T., Gallicano K D., Choudri S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceut Sci 2001 4 176-184
81. Greenblatt D J., Leigh-Pemberton R A., von Moltke L L. In vitro interactions of water-soluble garlic components with human cytochromes P450. J Nutr 2006 136 806S-809S
82. Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventative phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005 327 866-870
83. Engdal S, Nilsen O G. Inhibition of P-glycoprotein in Caco-2 cells: effects of herbal remedies frequently used by cancer patients. Xenobiotica 2008 38 559-573
84. Arora A, Seth K, Shukla Y. Reversal of P-glycoprotein-mediated multidrug resistance by diallyl sulfide in K562 leukemic cells and in mouse liver. Carcinogenesis 2004 25 941-949
85. Demeule M, Brossard M, Turcotte S, Regina A, Jodoin J, Bliveau R. Diallyl disulfide, a chemopreventive agent in garlic, induces multidrug resistance-associated protein 2 expression. Biochem Biophys Res Commun 2004 324 937-945
86. Berginc K, Zakelj S, Ursic D, Kristl A. Aged garlic extract stimulates P-glycoprotein and multidrug resistance associated protein 2 mediated effluxes. Biol Pharm Bull 2009 32 694-699
87. Berginc K, Zakelj S, Kristl A. In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetes patients. Eur J Nutr 2010 49 373-384
88. Berginc K, Trontelj J, Kristl A. The influence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacokinet 2010 25 307-313
89. Payen L, Sparfel L, Courtois A, Vernhet L, Guillouzo A, Fardel O. The drug efflux pump MRP-2: regulation of expression in physiopathological situations by endogenous and exogenous compounds. Cell Biol Toxicol 2002 18 221-233
90. Gurley B J., Gardner S F., Hubbard M A., Williams D K., Gentry W B., Cui Y, Ang C Y. W. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002 72 276-287
91. Gwilt P R., Lear C L., Tempero M A., Birt D D., Grandjean A C., Ruddon R W., Nagel D L. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 1994 3 155-160
92. Loizou G D., Crocker J. The effects of alcohol and diallyl sulphide on CYP2E1 activity in humans: a phenotyping study using chlorzoxazone. Hum Exp Toxicol 2001 20 321-327
93. Piscitelli S C., Burstein A H., Welden N, Gallicano K D., Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002 34 234-238
94. Gallicano K, Foster B, Choudri S. Effect of short-term administration of garlic supplements on single-dose pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003 55 199-202
95. Markowitz J S., DeVane L, Chavin K D., Taylor R M., Ruan Y, Donovan J L. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003 74 170-177
96. Jacek H, Rentsch K M., Steinert H C., Pauli-Magnus C, Meier P J., Fattinger K. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test [Abstr]. Clin Pharmacol Ther 2004 75 80
97. Jabbari A, Argani H, Ghorbanihaghjo A, Mahdavi R. Comparison between swallowing and chewing of garlic on levels of serum lipids, cyclosporine, creatinine and lipid peroxidation in renal transplant recipients. Lipids Health Dis 2005 4 11
98. Gurley B J., Gardner S F., Hubbard M A., Williams D K., Gentry W B., Cui Y, Ang C Y. W. Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John's wort, garlic oil, Panax ginseng and Ginkgo biloba. Drugs Aging 2005 22 525-539
99. Cox M C., Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter M G., Petros W P., Proce D K., Figg W D., Sparreboom A, Swain S M. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res 2006 12 4636-4640
100. Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr 2006 136 793S-795S
101. Abdul M I. M., Jiang X, Willaims K M., Day R O., Roufogalis B D., Liauw W S., Ku H, McLachlan A J. Pharmacodynamic interaction of warfarin with cranberry but not with garlic in healthy subjects. Br J Pharmacol 2008 154 1691-1700
102. Yang L-J, Fan L, Liu Z-Q, Mao Y-M, Guo D, Liu L-H, Tan Z-R, Peng L, Han C-T, Hu D-L, Wang D, Zhou H-H. Effects of allicin on CYP2C19 and CYP3A4 activity in healthy volunteers with different CYP2C19 genotypes. Eur J Clin Pharmacol 2009 65 601-608
103. Hajda J, Rentsch K M., Gubler C, Steinert H, Stieger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010 41 729-735
104. Chan P-C, Xia Q, Fu P P. Ginkgo biloba leaves extract: biological, medicinal, and toxicological effects. J Environ Sci Health C 2007 25 211-244
105. Zhou W, Chai H, Lin P H., Lumsden A B., Yao Q, Chen C. Clinical use and molecular mechanisms of action of extract of Ginkgo biloba leaves in cardiovascular diseases. Cardiovasc Drug Rev 2004 22 309-319
106. Canter P H., Ernst E. Ginkgo biloba is not a smart drug: an updated systematic review of randomized clinical trials testing the nootropic effects of G. biloba extracts in healthy people. Hum Psychopharmacol 2007 22 265-278
107. Ramassamy C, Longpr F, Christen Y. Ginkgo blioba extract (EGb 761) in Alzheimer's disease: is there any evidence? Curr Alzheimer Res 2007 4 253-262
108. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 2009 1 CD003120
109. Nicola S P., Kruidenier L M., Bendermacher B L., Prins M H., Teijink J A. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2009 2 CD006888
110. Kressman S, Mller W E., Blume H H. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002 54 661-669
111. Woelkert K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res 2010 24 445-450
112. Etheridge A S., Black S R., Patel P R., So J, Mathews J M. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. Planta Med 2007 73 731-741
113. Hellum B H., Hu Z, Nilsen O G. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary human hepatocytes. Basic Clin Pharmacol Toxicol 2007 100 23-30
114. Hellum B H., Hu Z, Nilsen O G. Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol 2009 105 58-63
115. Gaudineau C, Beckerman R, Welbourn S, Auclair K. Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract. Biochem Biophys Res Commun 2004 318 1072-1078
116. Chang T K. H., Chen J, Yeung E Y. H. Effect of Ginkgo biloba extract on procarcinogen-bioactivating human CYP1 enzymes: identification of isorhamnetin, kaempferol, and quercetin as potent inhibitors of CYP1B1. Toxicol Appl Pharmacol 2006 213 18-26
117. Numa A M., Abbott F S., Chang T K. H. Effect of Ginkgo biloba extract on oxidative metaolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype. Can J Physiol Pharmacol 2007 85 848-855
118. Lau A J., Chang T K. H. Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab Dispos 2009 37 1931-1937
119. Mohamed M F., Frye R F. Inhibition of intestinal and hepatic glucuronidation of mycophenolic acid by Ginkgo biloba extract and flavonoids. Drug Metab Dispos 2010 38 270-275
120. He N, Edeki T. The inhibitory effects of herbal components on CYP2C9 and CYP3A4 catalytic activities in human liver microsomes. Am J Ther 2004 11 206-212
121. Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol 2010 48 429-435
122. Tiong K H., Yiap B C., Tan E L., Ismail R, Ong C E. In vitro modulation of naturally occurring flavonoids on cytochrome P450 2A6 (CYP2A6) activity. Xenobiotica 2010 40 458-466
123. Kuo I F., Chen J, Chang T K. H. Effect of Ginkgo biloba extract on rat hepatic microsomal CYP1A activity: role of ginkgolides, bilobalide, and flavonols. Can J Physiol Pharmacol 2004 82 57-64
124. von Moltke L L., Weemhoff J L., Bedir E, Khan I A., Harmatz J S., Goldman P, Greenblatt D J. Inhibition of human cytochromes P450 by components of Ginkgo biloba. J Pharm Pharmacol 2004 56 1039-1044
125. Hodek P, Trefil P, Stiborov M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem Biol Interact 2002 139 1-21
126. Si D, Wang Y, Zhou Y-H, Guo Y, Wang J, Zhou H, Li Z-S, Fawcett J P. Mechanism of CYP2C9 inhibition by flavones and flavonols. Drug Metab Dispos 2009 37 629-634
127. He N, Xie H-G, Collins X, Edeki T, Yan Z. Effects of individual ginsenosides, ginkgolides and flavonoids on CYP2C19 and CYP2D6 activity in human liver microsomes. Clin Exp Pharmacol Physiol 2006 33 813-815
128. Chang T K. H., Chen J, Teng X W. Distinct role of bilobalide and ginkgolide A in the modulation of rat CYP2B1 and CYP3A23 gene expression by Ginkgo biloba extract in cultured hepatocytes. Drug Metab Dispos 2006 34 234-242
129. Yeung E Y. H., Sueyoshi T, Negishi M, Chang T H. K. Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab Dispos 2008 36 2270-2276
130. Deng Y, Bi H C., Zhao L Z., Wang X D., Chen J, Ou Z M., Ding L, Xu L J., Guan S, Chen X, Zhou S F., Huang M. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metab Lett 2008 2 60-66
131. Li L, Stanton J D., Tolson A H., Luo Y, Wang H. Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways. Pharm Res 2009 26 872-882
132. Rajaraman G, Yang G, Chen J, Chang T H. K. Modulation of CYP1B1 and CYP1A1 gene expression and activation of aryl hydrocarbon receptor by Ginkgo biloba extract in MCF-10A human mammary epithelial cells. Can J Physiol Pharmacol 2009 87 674-683
133. Satsu H, Hiura Y, Mochizuki K, Hamada M, Shimizu M. Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals. J Agric Food Chem 2008 56 5366-5373
134. Jeuken A, Keser B J. G., Khan E, Brouwer A, Koeman J, Denison M S. Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J Agric Food Chem 2003 51 5478-5487
135. Sasaki K, Hatta S, Wada K, Ueda N, Yoshimura T, Endo T, Sakata M, Tanaka T, Haga M. Effects of extract of Ginkgo biloba leaves and its constituents on carcinogen-metabolizing enzyme activities and glutathione levels in mouse liver. Life Sci 2002 70 1657-1667
136. Umegaki K, Saito K, Kubota Y, Sanada H, Yamada K, Shinozuka K. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn J Pharmacol 2002 90 345-351
137. Yang X F., Wang N P., Lu W H., Zeng F D. Effects of Ginkgo biloba extract and tanshinone on cytochrome P-450 isozymes and glutathione transferase in rats. Acta Pharmacol Sin 2003 24 1033-1038
138. Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Yamada K, Umegaki K. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food Chem Toxicol 2004 42 953-957
139. Chatterjee S S., Doelman C J., Nöldner M, Biber A, Koch E. Influence of the Ginkgo extract EGb 761 on rat liver cytochrome P450 and steroid metabolism and excretion in rats and man. J Pharm Pharmacol 2005 57 641-650
140. Guo L, Mei N, Liao W, Chan P-C, Fu P P. Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network. Omics 2010 14 75-89
141. Shinozuka K, Umekagi K, Kubota Y, Tanaka N, Mizuno H, Yamauchi J, Nakamura K, Kunitomo M. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 2002 70 2783-2792
142. Sugiyama T, Kubota Y, Shinozuka K, Yamada S, Wu J, Umegaki K. Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sci 2004 75 1113-1122
143. Kubota Y, Kobayashi K, Tanaka N, Nakamura K, Kunimoto M, Umegaki K, Shinozuka K. Pretreatment with Ginkgo biloba extract weakens the hypnosis action of phenobarbital and its plasma concentration in rats. J Pharm Pharmacol 2004 56 401-405
144. Zhao L-Z, Huang M, Chen J, Ee P L. R., Chan E, Duan W, Guan Y-Y, Hong Y-H, Chen X, Zhou S. Induction of propranolol metabolism by Ginkgo biloba extract EGb 761 in rats. Curr Drug Metab 2006 7 577-587
145. Yang C Y., Chao P D. L., Hou Y C., Tsai S Y., Wen K C., Hsiu S L. Marked decrease of cyclosporine bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol 2006 44 1572-1578
146. Tang J, Sun J, Zhang Y, Li L, Cui F, He Z. Herb-drug interactions: effect of Ginkgo biloba extract on the pharmacokinetics of theophylline in rats. Food Chem Toxicol 2007 45 2441-2445
147. Rajaraman G, Chen J, Chang T K. H. Ginkgolide A contributes to the potentiation of acetaminophen toxicity by Ginkgo biloba extract in primary cultures of rat hepatocytes. Toxicol Appl Pharmacol 2006 217 225-233
148. Umegaki K, Taki Y, Endoh K, Taku K, Tanabe H, Shinozuka K, Sugiyama T. Bilobalide in Ginkgo biloba extract is a major substance inducing hepatic CYPs. J Pharm Pharmacol 2007 59 871-877
149. Deng Y, Bi H-C, Zhao L-Z, He F, Liu Y-Q, Yu J-J, Ou Z-M, Ding L, Huang Z-Y, Huang M, Zhou S-F. Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica 2008 38 465-481
150. Taki Y, Yamazaki Y, Shimura F, Yamada S, Umegaki K. Time-dependent induction of hepatic cytochrome P450 enzyme activity and mRNA expression by bilobalide in rats. J Pharmacol Sci 2009 109 459-462
151. Yin O Q. P., Tomlinson B, Waye M M. Y., Chow A H. L., Chow M S. S. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004 14 841-850
152. Duche J C., Barre J, Guinot P, Duchier J, Cournot A, Tillement J P. Effect of Ginkgo biloba extract on microsomal enzyme induction. Int J Clin Pharm Res 1989 9 165-168
153. Smith M, Lin K M., Zheng Y P. An open trial of nifedipine-herb interactions: nifedipine with St John's wort, ginseng, or Ginkgo biloba [Abstr.]. Clin Pharmacol Ther 2001 69 P86
154. Sun H, Zuo Z, Yin O Q., Tomlinson B, Chow M S. A high-throughput cocktail method for screening the effect of herbal product on liver isozyme activities: experience with Ginkgo biloba. Clin Pharmacol Ther 2002 71 P100
155. Engelsen J, Nielsen J D., Winther K. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomized, double blind, placebo-crossover trial. Thromb Haemost 2002 87 1075-1076
156. Mauro V F., Mauro L S., Kleshinski J F., Khuder S A., Wang Y, Erhardt P W. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003 10 247-251
157. Markowitz J S., Donovan J L., DeVane L, Sipkes L, Chavin K D. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol 2003 23 576-581
158. Yoshioka M, Ohnishi N, Koishi T, Obata Y, Nakagawa M, Matsumoto T, Tagagi K, Takara K, Ohkuni T, Yokoyama T, Kuroda K. Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers. Biol Pharm Bull 2004 27 2006-2009
159. Yasui-Furukori N, Furukori H, Kaneda A, Kaneko S, Tateishi T. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004 44 538-542
160. Jiang X, Williams K M., Liauw W S., Ammit A J., Roufogalis B D., Duke C C., Day R O., McLachlan A J. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005 59 425-432
161. Markowitz J S., DeVane C L., Lewis J G., Chavin K D., Wang J-S, Donovan J L. Effect of Ginkgo biloba extract on plasma steroid concentrations in healthy volunteers: a pilot study. Pharmacotherapy 2005 25 1337-1340
162. Aruna D, Naidu M U. R. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2006 63 333-338
163. Mohutsky M A., Anderson G D., Miller J W., Elmer G W. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 2006 13 24-31
164. Greenblatt D J., von Moltke L L., Luo Y, Perloff E S., Horan K A., Bruce A, Reynolds R C., Harmatz J S., Avula B, Khan I A., Goldman P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol 2006 46 214-221
165. Lu W-J, Huang J, Lai M-L. The effects of ergoloid mesylates and Ginkgo biloba on the pharmacokinetics of ticlopidine. J Clin Pharmacol 2006 46 628-634
166. Uchida S, Yamada H, Li X D., Maruyama S, Ohmori Y, Oki T, Watanabe H, Umegaki K, Ohashi K, Yamada S. Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers. J Clin Pharmacol 2006 46 1290-1298
167. Wolf H R. D. Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily? Drugs R D 2006 7 163-172
168. Jiang X, Blair E Y. L., McLachlan A J. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006 46 1370-1378
169. Kudolo G B., Wang W, Javors M, Blodgett J. The effect of the ingestion of Ginkgo biloba extract (EGb 761) on the pharmacokinetics of metformin in non-diabetic and type 2 diabetic subjects - A double blind placebo-controlled, crossover study. Clin Nutr 2006 25 606-616
170. Robertson S M., Davey R T., Voell J, Formentini E, Alfaro R M., Penzak S R. Effect of Ginkgo biloba extract on lopinavir, midazolam, and fexofenadine pharmacokinetics in healthy subjects. Curr Med Res Opin 2008 24 591-599
171. Lei H P., Wang G, Wang L S., Ou-yang D, Chen H, Zhang W, Tan Z-R, Fan L, He Y-J, Zhou H-H. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers. Ann Pharmacother 2009 43 726-731
172. Fan L, Mao X-Q, Tao G Y., Wang G, Jiang F, Chen Y, Li Q, Zhang W, Lei H-P, Hu D L., Huang Y-F, Wang D, Zhou H-H. Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers. Xenobiotica 2009 39 249-254
173. Fan L, Tao G-Y, Wang G, Chen Y, Zhang W, He Y-J, Li Q, Lei H-P, Jiang F, Hu D-L, Huang Y-F, Zhou H-H. Effects of Ginkgo biloba extract ingestion on the pharmcokinetics of talinolol in healthy Chinese volunteers. Ann Pharmacother 2009 43 944-949
174. Lei H-P, Ji W, Lin J, Chen H, Tan Z-R, Hu D-L, Liu L-J, Zhou H-H. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol 2009 68 201-206
175. Zuo X-C, Zhang B-K, Jia S-J, Liu S-K, Zhou L-Y, Li J, Zhang J, Dai L-L, Chen B-M, Yang G-P, Yuan H. Effects of Ginkgo biloba extracts on diazepam metabolism: a pharmacokinetic study in healthy Chinese male subjects. Eur J Clin Pharmacol 2010 66 503-509
176. Kim B-H, Kim K-P, Lim K S., Kim J-R, Yoon S H., Cho J-Y, Lee Y-O, Lee K-H, Jang I-J, Shin S-G, Yu K-S. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: an open-label, randomized, two-period, two-treatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010 32 380-390
177. Food and Drug Administration. Drug Interaction Studies - Study Design, Data Analysis, and Implications for Dosing and Labeling. Available at: http://www.fda.gov/Drugs/Guidance%20Compliance%20Regulatory%20Information/ Guidances/ucm064982.htm Accessed 2010 Jul 17
178. Huang S M., Temple R, Throckmorton D C., Lesko L J. Drug interaction studies: study design, data analysis, and implications for dosing and labeling. Clin Pharmacol Ther 2007 81 298-304
179. Lau A J., Yang G, Rajaraman, Baucom C C., Chang T K. H. Species-dependent and receptor-selective action of bilobalide on the function of constitutive androstane receptor and preganane X receptor. Drug Metab Dispos 2012 40 178-186
180. Mauri P, Simonetti P, Gardana C, Minoggio M, Morazzoni P, Bombardelli E, Pietta P. Liquid chromatography/atmospheric pressure chemical ionization mass spectrometry of terpene lactones in plasma of volunteers dosed with Ginkgo biloba L. extracts. Rapid Commun Mass Spectrom 2001 15 929-934
181. Biber A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry 2003 36 S32-S37
182. Woelkart K, Feizlmayr E, Dittrich P, Beubler E, Pinl F, Suter A, Bauer R. Pharmacokinetics of bilobalide, ginkgolide A and B after administration of three different Ginkgo biloba L. preparations in humans. Phytother Res 2010 24 445-450
183. Kressmann S, Mller W E., Blume H H. Pharmaceutical quality of different Ginkgo biloba brands. J Pharm Pharmacol 2002 54 661-669
184. Kressmann S, Biber A, Wonnemann M, Schug B, Blume H H., Mller W E. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J Pharm Pharmacol 2002 54 1507-1514
185. Madgula V L., Avula B, Yu Y B., Tchantchou F, Fisher S, Luo Y, Khan I A., Khan S I. Intestinal and blood-brain barrier permeability of ginkgolides and bilobalide: in vitro and in vivo approaches. Planta Med 2010 76 599-606
186. Jia L, Zhao Y, Liang X-J. Current evaluation of the millennium phytomedicine - ginseng (II): collected chemical entities, modern pharmacology, and clinical applications emanated from traditional Chinese medicine. Curr Med Chem 2009 16 2924-2942
187. Vogler B K., Pittler M H., Ernst E. The efficacy of ginseng. A systematic review of randomized clinical trials. Eur J Clin Pharmacol 1999 55 567-575
188. Buettner C, Yeh G Y., Phillips R S., Mittleman M A., Kaptchuk T J. Systematic review of the effects of ginseng on cardiovascular risk factors. Ann Pharmacother 2005 39 83-95
189. Luo J Z., Luo L. Ginseng on hyperglycemia: effects and mechanisms. eCAM 2009 6 423-427
190. Christensen L P. Ginsenosides: chemistry, biosynthesis, analysis, and potential health effects. Adv Food Nutr Res 2008 55 1-99
191. Chen C, Choiu W, Zhang J. Comparison of the pharmacological effects of Panax ginseng and Panax quinquefolium. Acta Pharmacol Sin 2008 29 1103-1108
192. Tawab M A., Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M. Degradation of ginsenosides on humans after oral administration. Drug Metab Dispos 2003 31 1065-1071
193. Bae E-A, Han M J., Kim E-J, Kim D-H. Transformation of ginseng saponins to ginsenoside Rh2 by acids and human intestinal bacteria and biological activities of their transformants. Arch Pharm Res 2004 27 61-67
194. Lee J, Lee E, Kim D, Lee J, Yoo J, Koh B. Studies on absorption, distribution and metabolism of ginseng in humans after oral administration. J Ethnopharmacol 2009 122 143-148
195. Ling Y, Yong L, Chang-Xiao L. Metabolism and pharmacokinetics of ginsenosides. Asian J Pharmacodynam Pharmacokinet 2006 6 103-120
196. Hasegawa H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: metabolic activation of ginsenoside; deglycosylation by intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 2004 95 153-157
197. Han M, Fang X. Difference in oral absorption of ginsenoside Rg1 between in vitro and in vivo models. Acta Pharmacol Sin 2006 27 499-505
198. Xie H-T, Wang G-J, Chen M, Jiang X, Li H, Lv H, Huang C-R, Wang R, Roberts M. Uptake and metabolism of ginsenoside Rh2 and its aglycon protopanaxadiol by Caco-2 cells. Biol Pharm Bull 2005 28 383-386
199. Gu Y, Wang G-J, Wu X-L, Zheng Y-T, Zhang J-W, Ai H, Sun J-G, Jia Y-W. Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transporters. Xenobiotica 2010 40 602-612
200. Henderson G L., Harkey M R., Gershwin M E., Hackman R M., Stern J S., Stresser D M. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Pharmacol Lett 1999 65 209-214
201. Chang T K. H., Chen J, Benetton S A. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos 2002 30 378-384
202. 3. Biochem Pharmacol 2003 65 75-82
203. Liu Y, Zhang J-W, Li W, Ma H, Sun J, Deng M-C, Yang L. Ginsenoside metabolites, rather than naturally occurring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 2006 91 356-364
204. Liu Y, Ma H, Zhang J W., Deng M C., Yang L. Influence of ginsenoside Rh1 and F1 on human cytochrome p 450 enzymes. Planta Med 2006 72 126-131
205. Jin J, Shahi S, Kang H K., van Veen H W., Fan T-P. Metabolites of ginsenosides as novel BCRP inhibitors. Biochem Biophys Res Commun 2006 345 1308-1314
206. Kitagawa S, Takahashi T, Nabekura T, Tachikawa E, Hasegawa H. Inhibitory effects of ginsenosides and their hydrolyzed metabolites on daunorubicin transport in KB-C2 cells. Biol Pharm Bull 2007 30 1979-1981
207. Hao M, Zhao Y, Chen P, Huang H, Liu H, Jiang H, Zhang R, Wang H. Structure-activity relationship and substrate-dependent phenomena in effects of ginsenosides on activities of drug-metabolizing P450 enzymes. PLoS One 2008 3 e2697
208. Pokharel Y R., Kim N D., Han H K., Oh W K., Kang K W. Increased ubiquination of multidrug resistance 1 by ginsenoside Rd. Nutr Cancer 2010 62 252-259
209. Lee F C., Park J K., Ko J H., Lee J S., Kim K Y., Kim E K. Efects of Panax ginseng extract on the benzo(a)pyrene metabolizing enzyme system. Drug Chem Toxicol 1987 10 227-236
210. Lee Y J., Pantuck C B., Pantuck E J. Effect of ginseng on plasma levels of ethanol in the rat. Planta Med 1993 59 17-19
211. Gum S I., Jo S J., Ahn S H., Kim S G., Kim J T., Shin H M., Cho M K. The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[alpha]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J Ethnopharmacol 2007 112 568-576
212. Zhang R, Jie J, Zhou Y, Cao Z, Li W. Long-term effects of Panax ginseng on disposition of fexofenadine in rats in vivo. Am J Chin Med 2009 37 657-667
213. Zhu M, Chan K W., Ng L S., Chang Q, Chang S, Li R C. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol 1999 51 175-180
214. Yu C-T, Chen J, Teng X W., Tong V, Chang T K. H. Lack of evidence for induction of CYP2B1, CYP3A23, and CYP1A2 gene expression by Panax ginseng and Panax quinquefolius extracts in adult rats and primary cultures of rat hepatocytes. Drug Metab Dispos 2005 33 19-22
215. Anderson G D., Rosito G, Mohustsy M A., Elmer G W. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol 2003 43 643-648
216. Jiang X, Williams K M., Liauw W S., Ammit A J., Roufogalis B D., Duke C C., Day R O., McLachlan A J. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004 57 592-599
217. Lee L S., Wise S D., Chan C, Parsons T L., Flexner C, Lietman P S. Possible differential induction of phase 2 enzyme and antioxidant pathways by American ginseng, Panax quinquefolius. J Clin Pharmacol 2008 48 599-609
218. Lee S-H, Ahn Y-M, Ahn S-Y, Doo H-K, Lee B-C. Interaction between warfarin and Panax ginseng in ischemic stroke patients. J Altern Complement Med 2008 14 715-721
219. Andrade A S. A., Hendrix C, Parsons T L., Caballero B, Yuan C-S, Flexner C W., Dobs A S., Brown T T. Pharmacokinetic and metabolic effects of American ginseng (Panax quinquefolius) in healthy volunteers receiving the HIV protease inhibitor indinavir. BMC Complement Altern Med 2008 8 50
220. Lee F C., Ko J H., Park J K., Lee J S. Effects of Panax ginseng on blood alcohol clearance in man. Clin Exp Pharmacol Physiol 1987 14 543-546
221. Yuan C-S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. American ginseng reduces warfarin's effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004 141 23-27
222. Jiang X, Blair E Y. L., McLachlan A J. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006 46 1370-1378
223. Janetzky K, Morreale A P. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997 54 692-693
224. Rosado M F. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology 2003 99 111
225. Ames B N., Profet M, Gold L S. Dietary pesticides (99.99 % all natural). Proc Natl Acad Sci USA 1990 87 7777-7781
226. Murray M. Altered CYP expression and function in response to dietary factors: potential roles in disease pathogenesis. Curr Drug Metab 2006 7 67-81
227. Murray M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab 2000 1 67-84
228. Hodgson E, Philpot R M. Interaction of methylenedioxyphenyl (1,3-benzodioxole) compounds with enzymes and their effects on mammals. Drug Metab Rev 1974 3 231-301
229. Adams N H., Levi P E., Hodgson E. Regulation of cytochrome P-450 isozymes by methylenedioxyphenyl compounds. Chem Biol Interact 1993 86 255-274
230. Nakajima M, Suzuki M, Yamaji R, Takashina H, Shimada N, Yamazaki H, Yoko T. Isoform selective inhibition and inactivation of human cytochrome P450s by methylenedioxyphenyl compounds. Xenobiotica 1999 29 1191-1202
231. Chatterjee P, Franklin M R. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003 31 1391-1397
232. Gurley B J., Swain A, Hubbard M A., Hartsfield F, Thaden J, Williams D K., Gentry W B., Tong Y. Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo. Clin Pharmacol Ther 2008 83 61-69
233. Sandhu R S., Prescilla R P., Simonelli T M., Edwards D J. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol 2003 43 1283-1288
234. Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporine A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol 2005 61 567-572
235. Xin H-W, Wu X-C, Li Q, Yu A-R, Zhong M-Y, Liu Y-Y. The effects of berberine on the pharmacokinetics of ciclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol 2006 28 25-29
236. Pan G Y., Wang G J., Liu X D., Fawcett J P., Xie Y Y. The involvement of P-glycoprotein in berberine absorption. Pharmacol Toxicol 2002 91 193-197
237. Tsai P L., Tsai T H. Hepatobiliary excretion of berberine. Drug Metab Dispos 2004 32 405-412
238. Shitan N, Tanaka M, Terai K, Ueda K, Yazaki K. Human MDR1 and MRP1 recognize berberine as their transport substrate. Biosci Biotechnol Biochem 2007 71 242-245
239. Nies A T., Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol 2008 376 449-461
240. Qiu W, Jiang X H., Liu C X., Ju Y, Jin J X. Effect of berberine on the pharmacokinetics of substrates of CYP3A and P-gp. Phytother Res 2009 23 1553-1558
241. Gurley B J., Swain A, Barone G W., Williams D K., Breen P, Yates C R., Stuart L B., Hubbard M A., Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos 2007 35 240-245
242. Gurley B J. University of Arkansas for Medical Sciences, Little Rock. Personal communication. October 9, 2011.
243. Gupta P K., Gurley B J., Barone G, Hendrickson H P. Clinical pharmacokinetics and metabolism of berberine and hydrastine following an oral dose of goldenseal supplement. Planta Med 2010 76 546
244. Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf 2005 4 779-794
245. Ct C S., Kor C, Cohen J, Auclair K. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 2004 322 147-152
246. Unger M, Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun Mass Spectrom 2004 18 2273-2281
247. Mathews J M., Etheridge A S., Black S R. Inhibition of human cytochrome P450 activities by kava extract and kava lactones. Drug Metab Dispos 2002 30 1153-1157
248. Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet L Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (kava-kava). Planta Med 2002 68 1055-1058
249. Zou L, Henderson G L., Harkey M R., Sakai Y, Li A. Effects of kava (kava-kava, awa, yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 2004 11 285-294
250. Mathews J M., Etheridge A S., Valentine J L., Black S R., Coleman D P., Patel P, So J, Burka L T. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab Dispos 2005 33 1555-1563
251. Weiss J, Sauer A, Frank A, Unger M. Extracts and kavalactones of Piper methysticum G. Forst (kava-kava) inhibit P-glycoprotein in vitro. Drug Metab Dispos 2005 33 1580-1583
252. Raucy J L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos 2003 31 533-539
253. Ma Y, Sachdeva K, Liu J, Ford M, Yang D, Khan I A., Chichester C O., Yan B. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos 2004 32 1317-1324
254. Yueh M-F, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. Drug Metab Dispos 2005 33 38-48
255. Lim S T. S., Dragull K, Tang C-S, Bittenbender H C., Efird J T., Nerurkar P V. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol Sci 2007 97 214-221
256. Clayton N P., Yoshizawa K, Kissling G E., Burka L T., Chan P-C, Nyska A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp Toxicol Path 2007 58 223-236
257. Yamazaki Y, Hashida H, Arita A, Hamaguchi K, Shimura F. High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. Food Chem Toxicol 2008 46 3732-3738
258. Guo L, Li Q, Xia Q, Dial S, Chan P-C, Fu P. Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract. Food Chem Toxicol 2009 47 433-442
259. Russman S, Barguil Y, Cabalion P, Rentsch K, Wenk M. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther 2005 77 451-454
260. Srinivasan K. Black pepper and its pungent principle-piperine: a review of diverse physiological effects. Crit Rev Food Sci Nutr 2007 47 735-748
261. Atal C K., Zutshi U, Rao P G. Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol 1981 4 229-232
262. Friedman M, Levin C E., Lee S-U, Lee J-S, Ohnisi-Kameyama M, Kozukue N. Analysis by HPLC and LC/MS of pungent piperamides in commercial black, white, green, and red whole and ground peppercorns. J Agric Food Chem 2008 56 3028-3036
263. Dyer L A., Dodson C D., Richards J. Isolation, synthesis, and evolutionary ecology of Piper amides. In: Dyer L A. Palmer A N. editors Piper. A model genus for studies of evolution, chemical ecology, and trophic interactions. Boston Kluwer Academic Publishers 2004 117-139
264. Siddiqui B S., Gulzar T, Begum S, Afshan F, Sattar F A. Insecticidal amides from fruits of Piper nigrum Linn. Nat Prod Res 2005 19 143-150
265. Park I-K, Lee S-G, Shin S-C, Park J-D, Ahn Y-J. Larvicidal activity of isobutylamides identified in Piper nigrum fruits against three mosquito species. J Agric Food Chem 2002 50 1866-1870
266. Atal C K., Dubey R K., Singh J. Biochemical basis of enhanced drug bioavailability by piperine: evidence that piperine is a potent inhibitor of drug metabolism. J Pharmacol Exp Ther 1985 232 258-262
267. Singh J, Dubey R K., Atal C K. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogenous UDP-glucuronic acid content. J Pharmacol Exp Ther 1986 236 488-493
268. Dalvi R R., Dalvi P S. Differences in the effects of piperine and piperonyl butoxide on hepatic drug-metabolizing enzyme system in rats. Drug Chem Toxicol 1991 14 219-229
269. Reen R K., Singh J. In vitro and in vivo inhibition of pulmonary cytochrome P450 activities by piperine, a major ingredient of Piper species. Indian J Exp Biol 1991 29 568-573
270. Reen R K., Jamwal D S., Taneja S C., Koul J L., Dubey R K., Wiebel F J., Singh J. Impairment of UDP-glucose dehydrogenase and glucuronidation activities in liver and small intestine of rat and guinea pig in vitro by piperine. Biochem Pharmacol 1993 46 229-238
271. Reen R K., Roesch S F., Kiefer F, Wiebel F J., Singh J. Piperine impairs cytochrome P4501A1 activity by direct interaction with the enzyme and not by down regulation of CYP1A1 gene expression in the rat hepatoma 5 L cell line. Biochem Biophys Res Commun 1996 218 562-569
272. Reen R K., Wiebel F J., Singh J. Piperine inhibits aflatoxin B1-induced cytotoxicity and genotoxicity in V79 Chinese hamster cells genetically engineered to express rat cytochrome P4502B1. J Ethnopharmacol 1997 58 165-173
273. Koul S, Koul J L., Taneja S C., Dhar K L., Jamwal D S., Singh K, Reen R K., Singh J. Structure-activity relationship of piperine and its synthetic analogues for their inhibitory potentials of rat hepatic microsomal constitutive and inducible cytochrome P450 activities. Bioorg Med Chem 2000 8 251-268
274. Bhardwaj R K., Glaeser H, Becquemont L, Klotz U, Gupta S K., Fromm M F. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002 302 645-650
275. Subehan, Usia T, Kadota S, Tezuka Y. Mechanism-based inhibition of human liver microsomal cytochrome P450 2D6 (CYP2D6) by alkamides of Piper nigrum. Planta Med 2006 72 527-532
276. Suresh D, Srinivasan K. Influence of curcumin, capsaicin, and piperine on the rat liver drug-metabolizing enzyme system in vivo and in vitro. Can J Physiol Pharmacol 2006 84 1259-1265
277. Volak L P., Ghirmai S, Cashman J R., Court M H. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor. Drug Metab Dispos 2008 36 1594-1605
278. Han Y, Tan T M. C., Lim L-Y. In vitro and in vivo evaluation of the effects of piperine on P-gp function and expression. Toxicol Appl Pharmacol 2008 230 283-289
279. Hiwale A R., Dhuley J N., Naik S R. Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats. Indian J Exp Biol 2002 40 277-281
280. Aher S, Biradar S, Gopu C L., Paradkar A. Novel pepper extract for enhanced P-glycoprotein inhibition. J Pharm Pharmacol 2009 61 1179-1186
281. Okura T, Ibe M, Umegaki K, Shinozuka K, Yamada S. Effects of dietary ingredients on function and expression of P-glycoprotein in human intestinal epithelial cells. Biol Pharm Bull 2010 33 255-259
282. Najar I A., Sachin B S., Sharma S C., Satti N K., Suri K A., Johri R K. Modulation of P-glycoprotein ATPase activity by some phytoconstituents. Phytother Res 2010 24 454-458
283. Jin M J., Han H K. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction. J Food Sci 2010 75 H93-H96
284. Selvendiran K, Thirunavukkarasu C, Singh J P. V., Padmavathi R, Sakthisekaran D. Chemopreventative effect of piperine on mitochrondrial TCA cycle and phase-I and glutathione-metabolizing enzymes in benzo(a)pyrene induced lung carcinogenesis in Swiss albino mice. Mol Cell Biochem 2005 271 101-106
285. Dalvi R R., Dalvi P S. Comparison of the effects of piperine administered intragastrically and intraperitoneally on the liver and liver mixed-function oxidases on rats. Drug Metabol Drug Interact 1991 9 23-30
286. Kang M H., Won S M., Park S S., Kim S G., Novak R F., Kim N D. Piperine effects on the expression of P4502E1, P4502B, and P4501A in rat. Xenobiotica 1994 24 1195-1204
287. Khajuria A, Thusu N, Zutshi U. Piperine modulates permeability characteristics of intestine by inducing alterations in membrane dynamics: influence on brush border membrane fluidity, ultrastructure and enzyme kinetics. Phytomedicine 2002 9 224-231
288. Zutshi R K., Singh R, Zutshi U, Johri R K., Atal C K. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. JAPI 1985 33 223-224
289. Bano G, Amla V, Raina R K., Zutshi U, Chopra C L. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 1987 53 568-569
290. Bano G, Raina R K., Zutshi U, Bedi K L., Johri R K., Sharma S C. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991 41 615-617
291. Velpandian T, Jasuja R, Bhardwaj R K., Jaiseal J, Gupta S K. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 2001 26 241-248
292. Pattanaik S, Hota D, Prabhakar S, Kharbanda P, Pandhi P. Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy. Phytother Res 2006 20 683-686
293. Kasibhatta R, Naidu M U. R. Influence of piperine on the pharmacokinetics of nevirapine under fasting conditions: a randomized, crossover, placebo-controlled study. Drugs R D 2007 8 383-391
294. Anand P, Kunnumakkara A B., Newman R A., Aggarwal B B. Bioavailability of curcumin: problems and promises. Mol Pharmacol 2007 4 807-818
295. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol 2009 6 192-199
296. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas P S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998 64 353-356
297. Lambert J D., Hong J, Kim D H., Mishin V M., Yang C S. Piperine enhances the bioavailability of the tea polyphenol ()-epigallocatechin-3-gallate in mice. J Nutr 2004 134 1948-1952
298. Panossian A, Wikman G. Pharmacology of Schisandra chinensis Bail.: an overview of Russian research and uses in medicine. J Ethnopharmacol 2008 118 183-212
299. Schisandra monograph. Natural Medicines Comprehensive Database. Available at: http://naturaldatabase.therapeuticresearch.com Accessed October 26, 2010
300. Pan Q, Tao W, Lu Q, Hu X. Schisandrin B - a novel inhibitor of P-glycoprotein. Biochem Biophys Res Commun 2005 335 406-411
301. Pan Q, Lu Q, Zhang K, Hu X. Dibenzocyclooctadiene lingnans: a class of novel inhibitors of P-glycoprotein. Cancer Chemother Pharmacol 2006 58 99-106
302. Wan C-K, Zhu G-Y, Shen X-L, Chattopadhyay A, Dey S, Fong W-F. Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 2006 72 824-837
303. Yoo H H., Lee M, Lee M W., Lim S Y., Shin J, Kim D-H. Effects of Schisandra lignans on P-glycoprotein-mediated efflux in human intestinal Caco-2 cells. Planta Med 2007 73 444-450
304. Madgula V L. M., Avula B, Choi Y W., Pullela S V., Khan I A., Walker L A., Khan S I. Transport of Schisandra chinensis extract and its biologically-active constituents across Caco-2 cell monolayers - an in vit ro model of intestinal transport. J Pharm Pharmacol 2008 60 363-370
305. Huang M, Jin J, Sun H, Liu G T. Reversal of P-glycoprotein-mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae. Cancer Chemother Pharmacol 2008 62 1015-1026
306. Slaninov I, Brezinov L, Koubikov L, Slanina J. Dibenzocyclooctadiene lignans overcome drug resistance in lung cancer cells - study of structure-activity relationship. Toxicol In Vitro 2009 23 1047-1054
307. Iwata H, Tezuka Y, Usia T, Kadota S, Hiratsuka A, Watabe T. Inhibition of human liver microsomal CYP3A4 and CYP2D6 by extracts from 78 herbal medicines. J Tradit Med 2004 21 42-50
308. Iwata H, Tezuka Y, Kadota S, Hiratuska A, Watabe T. Identification and characterization of potent CYP3A4 inhibitors in Schisandra fruit extract. Drug Metab Dispos 2004 32 1351-1358
309. Makino T, Mizuno F, Mizukami H. Does a Kampo medicine containing Schisandra fruit affect pharmacokinetics of nifedipine like grapefruit juice? Biol Pharm Bull 2006 29 2065-2069
310. Mu Y, Zhang J, Zhang S, Zhou H-H, Toma D, Ren S, Huang L, Yaramus M, Baum A, Venkataramanan R, Xie W. Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther 2006 316 1369-1377
311. Lai L, Hao H, Wang Q, Zheng C, Zhou F, Liu Y, Wang Y, Yu G, Kang A, Peng Y, Wang G, Chen X. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos 2009 37 2399-2407
312. Qin X L., Bi H C., Wang X D., Li J L., Wang Y, Xue X P., Chen X, Wang C X., Xu L J., Wang Y T., Huang M. Mechanistic understanding of the different effects of Wuzhi tablet (Schisandra sphenanthera extract) on the absorption and first-pass intestinal and hepatic metabolism of tacrolimus (FK506). Int J Pharm 2010 389 114-121
313. Lee S B., Kim C Y., Lee H J., Yun J H., Nho C W. Induction of the phase II detoxification enzyme NQO1 in hepatocarcinoma cells by lignans from the fruit of Schisandra chinensis through nuclear accumulation of Nrf2. Planta Med 2009 75 1314-1318
314. Jin J, Bi H, Hu J, Zhong G, Zhao L, Huang Z, Huang M. Enhancement of oral bioavailability of paclitaxel after oral administration of schisandrol B in rats. Biopharm Drug Dispos 2010 31 264-268
315. Liu K-T, Cresteil T, Columelli S, Lesca P. Pharmacological properties of dibenzo[ a,c ]cyclooctene derivatives isolated from Fructus Schizandrae chinensis. II. Induction of phenobarbital-like hepatic monooxygenases. Chem Biol Interact 1982 39 315-319
316. Salbe A D., Bjeldanes L F. The effects of dietary Brussels sprouts and Schizandra chinensis on the xenobiotic-metabolizing enzymes of the rat small intestine. Food Chem Toxicol 1985 23 57-65
317. Xin H-W, Wu X-C, Li Q, Yu A-R, Zhu M, Shen Y, Su D, Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol 2007 64 469-475
318. Jiang W, Wang X, Xu X, Kong L. Effect of Schisandra sphenanthera extract on the concentration of tacrolimus in the blood of liver transplant patients. Int J Clin Pharmacol Ther 2010 48 224-229
319. Xin H-W, Wu X-C, Li Q, Yu A-R, Xiong L. Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers. Br J Clin Pharmacol 2009 67 541-546
320. Morazzoni P, Bombardelli E. Silybum marianum (Carduus marianus). Fitoterapia 1995 64 3-42
321. Kroll D J., Shaw H S., Oberlies N H. Milk thistle nomenclature: why it matters in cancer research and pharmacokinetic studies. Integr Cancer Ther 2007 6 110-119
322. Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001 61 2035-2063
323. Rambaldi A, Jacobs B P., Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005 100 2583-2591
324. Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther 2007 6 146-157
325. Saller R, Brignoli R, Melzer J, Meier R. An updated systematic review with meta-analysis for the clinical evidence of silymarin. Forsch Komplementmed 2008 15 9-20
326. El-Kamary S S., Shardell M D., Abdel-Hamid M, Ismail S, El-Ateek M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, El-Kassas M, Esmat G, Strickland G T. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis. Phytomedicine 2009 16 391-400
327. Lorenz D, Lcker P W., Mennicke W H., Wetzelsberger N. Pharmacokinetic studies with silymarin in human serum and bile. Methods Find Exp Clin Pharmacol 1984 6 655-661
328. Kim Y C., Kim E J., Lee E D., Kim J H., Jang S W., Kim Y G., Kwon J W., Kim W B., Lee M G. Comparative bioavailability of silibinin in healthy male volunteers. Int J Clin Pharmacol Ther 2003 41 593-596
329. Schrieber S J., Wen Z, Vourvahis M, Smith P C., Fried M W., Kashuba A D. M., Hawke R L. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab Dispos 2008 36 1909-1916
330. Wen Z, Dumas T E., Schrieber S J., Hawke R L., Fried M W., Smith P C. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 2008 36 65-72
331. Hawke R L., Schrieber S J., Soule T A., Wen Z, Smith P C., Reddy R, Wahed A S., Belle S H., Afdhal N H., Navarro V J., Berman J, Liu Q-Y, Doo E, Fried M W. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C. J Clin Pharmacol 2010 50 434-449
332. Miguez M-P, Anundi I, Sainz-Pardo L A., Lindros K O. Hepatoprotective mechanism of silymarin: no evidence for involvement of cytochrome P450 2E1. Chem Biol Interact 1994 91 51-63
333. Venkataramanan R, Ramachandran V, Komoroski B J., Zhang S, Schiff P L., Strom S C. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000 28 1270-1273
334. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Böcker R H., Beckurts T, Lang W, Hunz M, Fuhr U. Inhibitory effects of silibin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000 86 250-256
335. Zuber R, Modriansk M, Dvork Z, Rohovsk P, Ulrichov J, Simnek V, Anzenbacher P. Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 2002 16 632-638
336. Sridar C, Goosen T C., Kent U M., Williams J A., Hollenberg P F. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyl-transferases. Drug Metab Dispos 2004 32 587-594
337. Patel J, Buddha B, Dey S, Pal D, Mitra A K. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 2004 11 262-277
338. Jancova P, Anzenbacherova E, Papouskova B, Lemr K, Luzna P, Veinlichova A, Anzenbacher P, Simanek V. Silybin is metabolized by cytochrome P450 2C8 in vitro. Drug Metab Dispos 2007 35 2035-2039
339. Doehmer J, Tewes B, Klein K-U, Gritzko K, Muschick H, Mengs U. Assessment of drug-drug interaction for silymarin. Toxicol In Vitro 2008 22 610-617
340. Brantley S J., Oberlies N H., Kroll D J., Paine M F. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations. J Pharmacol Exp Ther 2010 332 1081-1087
341. Maitrejean M, Comte G, Barron D, El Kirat K, Conseil G, Di Pietro A. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 2000 10 157-160
342. Zhang S, Morris M E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003 304 1258-1267
343. Zhang S, Morris M E. Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharm Res 2003 20 1184-1191
344. Chung S Y., Sung M K., Kim N H., Jang J O., Go E J., Lee H J. Inhibition of P-glycoprotein by natural products in human breast cancer cells. Arch Pharm Res 2005 28 823-828
345. Morris M E., Zhang S. Flavonoid-drug interactions: effects of flavonoids on ABC transporters. Life Sci 2006 78 2116-2130
346. Miranda S R., Lee J K., Brouwer K L. R., Wen Z, Smith P C., Hawke R L. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2). Drug Metab Dispos 2008 36 2219-2226
347. Deng J W., Shon J-H, Shin H-J, Park S-J, Yeo C-W, Zhou H-H, Song P-S, Shin J-G. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin. Pharm Res 2008 25 1807-1814
348. Javed S, Kohli K, Ali M. Patented bioavailability enhancement techniques of silymarin. Recent Pat Drug Deliv Formul 2010 4 145-152
349. Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E. Pharmacokinetic studies on Idb 1016, a silybin-phosphatidylcholine complex, in normal human subjects. Eur J Drug Metab Pharmacokinet 1990 15 333-338
350. Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther 1994 32 614-617
351. Kidd P, Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: a silybin-phosphatidylcholine complex (Siliphos). Altern Med Rev 2005 10 193-203
352. Kidd P M. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extracts. Altern Med Rev 2009 14 226-246
353. Flaig T W., Gustafson D L., Su L-J, Zirrolli J A., Crighton F, Harrison G S., Pierson A S., Agarwal R, Glod L M. A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients. Invest New Drugs 2007 25 139-146
354. Flaig T W., Glod M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su L-J, Li Y, Harrison G, Agarwal R, Crawford E D., Lucia M S., Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 2010 70 848-855
355. Leber H W., Knauff S. Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung 1976 26 1603-1605
356. Piscitelli S C., Formentini E, Burstein A H., Alfaro R, Jagannatha S, Falloon J. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002 22 551-556
357. Mills E, Wilson K, Clarke M, Foster B, Walker S, Rachlis B, DeGroot N, Montori V M., Gold W, Phillips E, Myers S, Gallicano K. Milk thistle and indinavir: a randomized controlled pharmacokinetics study and meta analysis. Eur J Clin Pharmacol 2005 61 1-7
358. DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, Morse G. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003 23 866-870
359. van Erp N P. H., Baker S D., Zhao M, Rudek M A., Guchelaar H-J, Nortier J W. R., Sparreboom A, Gelderblom H. Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan. Clin Cancer Res 2005 11 7800-7806
360. Fuhr U, Beckmann-Knopp S, Jetter A, Lck H, Mengs U. The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 2007 73 1429-1435
361. Rao B N., Srinivas M, Kumar Y S., Rao Y M. Effect of silymarin on the oral bioavailability of ranitidine in healthy human volunteers. Drug Metabol Drug Interact 2007 22 175-185
362. Han Y, Guo D, Chen Y, Tan Z-R, Zhou H-H. Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers. Xenobiotica 2009 39 694-699
363. Rajnarayana K, Reddy M S., Vidyasagar J, Krishna D R. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004 54 109-113
364. Han Y, Guo D, Chen Y, Chen Y, Tan Z-R, Zhou H-H. Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers. Eur J Clin Pharmacol 2009 65 585-591
365. Ladas E J., Kroll D J., Oberlies N H., Cheng B, Ndao D H., Rheingold S R., Kelly K M. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer 2010 116 506-513
366. Hypericum Depression Trial Study Group. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 2002 14 1807-1814
367. Linde K, Berner M M., Kriston L. St. John's wort for major depression. Cochrane Database Syst Rev 2008 4 CD000448
368. Beerhues L. Hyperforin. Phytochemistry 2006 67 2201-2207
369. Nahrstedt A, Butterweck V. Lessons learned from herbal medicinal products: the example of St John's wort. J Nat Prod 2010 73 1015-1021
370. Madabushi R, Frank B, Drewelow B, Derendorf H, Butterweck V. Hyperforin in St. John's wort interactions. Eur J Clin Pharmacol 2006 62 225-233
371. Whitten D L., Myers S P., Hawrelak J A., Wohlmuth H. The effect of St. John's wort extract on CYP3A: a systematic review of prospective clinical trials. Br J Clin Pharmacol 2006 62 512-526
372. Zhou S-F, Lai X. An update on clinical drug interactions with the herbal antidepressant St John's wort. Curr Drug Metab 2008 9 394-409
373. Kober M, Pohl K, Efferth T. Molecular mechanisms underlying St. John's wort drug interactions. Curr Drug Metab 2008 9 1027-1037
374. Borrelli F, Izzo A A. Herb-drug interactions with St John's wort (Hypericum perforatum): an update on clinical observations. AAPS J 2009 11 710-727
375. Moore L B., Goodwin B, Jones S A., Wisely W B., Serabjit-Singh C J., Willson T M., Collins J L., Kliewer S A. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000 97 7500-7502
376. Wentworth J M., Agostini M, Love J, Schwabe J W., Chatterjee V K. K. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000 166 R11-R16
377. Watkins R E., Maglich J M., Moore L B., Wisely G B., Noble S M., Davis-Searlies P R., Lambert M H., Kliewer S A., Redinbo M R. 2.1 crystal structure of human PXR in complex with the St John's wort compound hyperforin. Biochemistry 2003 42 1430-1438
378. Caccia S. Antidepressant-like components of Hypericum perforatum extracts: an overview of their pharmacokinetics and metabolism. Curr Drug Metab 2005 6 531-543
379. Wurglics M, Schubert-Zsilavecz M. Hypericum perforatum: a modern herbal antidepressant, pharmacokinetics of active ingredients. Clin Pharmacokinet 2006 45 449-468
380. Wurglics M, Westerhoff K, Kaunzinger A, Wilke A, Baumeister A, Dressman J, Schubert-Zsilavecz M. Comparison of german St. John's wort products according to hyperforin and total hypericin content. J Am Pharm Assoc 2001 41 560-566
381. Gödtel-Armbrust U, Metzger A, Kroll U, Kelber O, Wojnowski L. Variability in PXR-mediated induction of CYP3A4 by commercial preparations and dry extracts of St. John's wort. Nauyn Schmiedebergs Arch Pharmacol 2007 375 377-382
382. Mai I, Bauer S, Perloff E S., Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John's wort-cyclosporine drug interaction. Clin Pharmacol Ther 2004 76 330-340
383. Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin H, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St. John's wort extract. Planta Med 2005 71 331-337
384. Mueller S C., Majcher-Peszynska J, Uehleke B, Klammt S, Mundkowski R G., Miekisch W, Sievers H, Bauer S, Frank B, Kundt G, Drewelow B. The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 2006 62 29-36
385. Wang X D., Li J L., Su Q B., Guan S, Chen J, Du J, He Y W., Zeng J, Zhang J X., Chen X. Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John's wort-induced activity of cytochrome P450 3A4 enzyme. Br J Clin Pharmacol 2009 67 255-261
386. Imai H, Kotegawa T, Tsutsumi K, Morimoto T, Eshima N, Nakano S, Ohashi K. The recovery time-course of CYP3A after induction by St John's wort administration. Br J Clin Pharmacol 2008 65 701-707
387. Ajazuddin S S. Applications of novel drug delivery system for herbal formulations. Fitoterapia 2010 81 680-689
388. Gurley B J. Emerging technologies for improving phytochemical bioavailability: benefits and risks. Clin Pharmacol Ther 2011 89 915-919
389. Portoles A, Terleira A, Calvo A, Martinez I, Resplandy G. Effects of Hypericum perforatum on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial. J Clin Pharmacol 2006 46 1188-1194
390. Drr D, Stieger B, Kullak-Ublick G A., Rentsch K M., Steinert H C., Meier P J., Fattinger K. St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000 68 598-604
391. Johne A, Schmider J, Brockmoller J, Stadelmann A M., Stormer E, Bauer S, Scholler G, Langheinrich M, Roots I. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John's wort (Hypericum perforatum). J Clin Psychopharmacol 2002 22 46-54
392. Mueller S C., Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl E M., Sievers H, Frank B, Riethling A K., Drewelow B. Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther 2004 75 546-557
393. Wang L S., Zhu B, El-Aty A M., Zhou G, Li Z, Wu J, Chen G L., Jie L, Tang Z R., Wang A. The influence of St. John's wort on CYP2C19 activity with respect to genotype. J Clin Pharmacol 2004 44 577-581
394. Rengelshausen J, Banfield M, Riedel K, Burhenne J, Weiss J, Thomsen T, Walter-Sack I, Haefeli W, Mikus G. Opposite effects of short-term and long-term St John's wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005 78 25-33
395. Dresser G K., Schwarz U I., Wilkinson G R., Kim R B. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 2005 73 41-50
396. Wang Z, Hamman M A., Huang S M., Lesko L J., Hall S D. Effect of St John's wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002 71 414-420
397. Xie R, Tan L H., Polasek E C., Hong C, Teillol-Foo M, Gordi T, Sharma A, Nickens D J., Arakawa T, Knuth D W. CYP3A and P-glycoprotein activity induction with St. John's wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005 45 352-356
398. Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakamoto K, Masada M, Miyamori I. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001 70 518-524
399. Andren L, Andreasson , Eggertsen R. Interaction between a commercially available St. John's wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol 2007 63 913-916
400. Wang Z, Gorski C, Hamman M A., Huang S-M, Lesko L J., Hall S D. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001 70 317-326
401. Markowitz J S., DeVane C L., Boulton D W., Carson S W., Nahas Z, Risch S C. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000 66 133-139
402. Markowitz J S., Donovan J L., DeVane C L., Taylor R M., Ruan Y, Wang J S., Chavin K D. Effect of St John's wort on drug metabolism by induction of cytochrome P450 3A4 enzyme. JAMA 2003 290 1500-1504
403. Kawaguchi A, Ohmori M, Tsuruoka S-I, Nishiki K, Harada K, Miyamori I, Yano R-I, Nakamura T, Masada M, Fujimura A. Drug interaction between St John's wort and quazepam. Br J Clin Pharmacol 2004 58 403-410
404. de Maat M M., Hoetelmans R M., Math t R A., van Gorp E C., Meenhorst P L., Mulder J W., Beijnen J H. Drug interaction between St John's wort and nevirapine. AIDS 2001 15 420-421
405. Schwarz U, Hanso H, Dresser G, Kim R, Fromm M, Oertel R, Miehlke S, Kirch W. St. John's wort reduces oral bioavailability of talinolol in healthy volunteers. Clin Pharmacol Ther 2002 71 P33
406. Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernas H. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism. Clin Pharmacol Ther 2004 75 298-309
407. Mathijssen R H., Verweij J, de Bruijn P, Loos W J., Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002 94 1247-1249
408. Frye R F., Fitzgerald S M., Lagattuta T F., Hruska M W., Egorin M J. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004 76 323-329
409. Smith P. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004 24 1508-1514
410. Hall S D., Wang Z, Huang S M., Hamman M A., Vasavada N, Adigun A Q., Hilligoss J K., Miller M, Gorski J C. The interaction between St John's wort and an oral contraceptive. Clin Pharmacol Ther 2003 74 525-535
411. Murphy P A., Kern S E., Stanczyk F Z., Westhoff C L. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception 2005 71 402-408
412. Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol 2003 56 683-690
413. Xu H, Williams K M., Liauw W S., Murray M, Day R O., McLachlan A J. Effects of St John's wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 2008 153 1579-1586
414. Barone G W., Gurley B J., Ketel B L., Lightfoot M L., Abul-Ezz S R. Drug interaction between St John's wort and cyclosporine. Ann Pharmacother 2000 34 1013-1016
415. Barone G W., Gurley B J., Ketel B L., Abul-Ezz S R. Herbal dietary supplements: a source for drug interactions in transplant recipients. Transplantation 2001 71 239-241
416. Bauer S, Starmer E, Johne A, Krager H, Budde K, Neumayer H-H, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients. Br J Clin Pharmacol 2003 55 203-211
417. Bolley R, Zulke C, Kammerl M, Fischereder M, Kramer B K. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. Transplantation 2002 73 1009
418. Hebert M F., Jeong M P., Yu-Luan C, Shahzad A, Anne M L. Effects of St. John's wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 2004 44 89-94
419. Mai I, Budde K, Starmer E, Bauer S, Krager H, Roots I. Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003 18 819-822
420. Eich-Hochli D, Oppliger R, Golay K P., Baumann P, Eap C B. Methadone maintenance treatment and St. John's wort - a case report. Pharmacopsychiatry 2003 36 35-37
421. Wang L S., Zhou G, Zhu B, Wu J, Wang J G., Abd El-Aty A M., Li T, Liu J, Yang T L., Wang D. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther 2004 75 191-197
422. Lundahl A, Hedeland M, Bondesson U, Knutson L, Lennernas H. The effect of St. John's wort on the pharmacokinetics, metabolism and biliary excretion of finasteride and its metabolites in healthy men. Eur J Pharm Sci 2009 36 433-443